RT Book, Section
A1 O'Connell, Charles W.
A2 Olson, Kent R.
A2 Anderson, Ilene B.
A2 Benowitz, Neal L.
A2 Blanc, Paul D.
A2 Clark, Richard F.
A2 Kearney, Thomas E.
A2 Kim-Katz, Susan Y.
A2 Wu, Alan H. B.
SR Print(0)
ID 1179990507
T1 ANTICOAGULANTS, NEWER
T2 Poisoning & Drug Overdose, 7e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9780071839792
LK accessmedicine.mhmedical.com/content.aspx?aid=1179990507
RD 2024/04/24
AB The  newer  target-specific  oral  anticoagulant  medications  dabigatran,  rivaroxaban,  apixaban,  and  edoxaban  have  become  increasingly  popular  alternatives  to  the  vitamin  K  antagonist,  warfarin  (see  Warfarin  and  Superwarfarins),  the  former  mainstay  of  oral  anticoagulation  for  prevention  and  treatment  of  venous  thrombus  events  and  stroke  risk  reduction  in  atrial  fibrillation.  These  newer  drugs  inhibit  a  single  target-specific  step  in  coagulation  rather  than  blocking  multiple  vitamin  K–dependent  blood  factors  as  done  by  warfarin.